# US 2026/0092275 A1 · Products and compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0092275 A1
- Document ID: US20260092275A1
- Status: Published application
- Kind: A1
- Application number: 19/082,089
- Filed: 2025-03-17
- Published: 2026-04-02
- Earliest claimed: 2022-09-16
- Assignees: Sirnaomics, Inc.
- Applicants: Sirnaomics, Inc.
- Inventors: Dmitry SAMARSKY
- Web page: https://patentgrep.com/patent/US20260092275A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 31/712: Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/313: Phosphorodithioates
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/322: 2'-R Modification
- C12N 2310/351: Conjugate
- C12N 2310/3519: Fusion with another nucleic acid
- C12N 2320/31: Combination therapy
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Nucleic acid products and compositions are provided, together with methods for their use, to modulate, in particular, interfere with or inhibit CFB and C5 gene expression.

## Claims

### Claim 1

A nucleic acid construct comprising at least:
(a) a first nucleic acid sequence that is complementary to a first portion of an RNA which is transcribed from a targeted CFB gene;
(b) a second nucleic acid sequence that is complementary to a second portion of an RNA which is transcribed from a targeted C5 gene;
(c) a third nucleic acid sequence that is at least partially complementary to said first nucleic acid portion of (a), so as to form a first nucleic acid duplex region therewith;
(d) a fourth nucleic acid sequence that is at least partially complementary to said second nucleic acid portion of (b), so as to form a second nucleic acid duplex region therewith,
wherein the first nucleic acid sequence of (a) is directly linked to the fourth nucleic acid sequence of (d) and the second nucleic acid of (b) is directly linked to the third nucleic acid sequence of (c);
wherein the construct contains labile sites such that subsequent to in vivo administration the construct is cleaved at said labile sites to yield at least first and second discrete nucleic acid targeting molecules that respectively target the RNA portions transcribed from the targeted genes of (a) and (b);
wherein the
wherein (i) the first nucleic acid targeting molecule modulates expression of the target gene of (a), and comprises, or is derived from, the first nucleic acid portion of (a), and (ii) the second nucleic acid targeting molecule modulates expression of the targeted gene of (b), and comprises, or is derived from, the second nucleic acid portion of (b).

### Claim at position 2

2-4. (canceled)

### Claim 5 (depends on 1)

The construct according to claim 1, wherein said labile sites comprise one or more unmodified nucleotides.

### Claim at position 4

6-8. (canceled)

### Claim 9 (depends on 1)

The construct according to claim 1, wherein
(a) said first nucleic acid sequence is selected from the group consisting of SEQ ID Nos. 1-252;
(b) said second nucleic acid sequence is selected from the group consisting of SEQ ID Nos. 504-754;
(c) said third nucleic acid sequence is selected from the group consisting of SEQ ID Nos 253-504; and/or
(d) said fourth nucleic acid sequence is selected from the group consisting of SEQ ID Nos. 755-1004,
wherein said third and fourth nucleobase sequences, to the extent they have a length of 15 nucleobases, may be shorter by one, two, three or four nucleobases, and to the extent they have a length of 14 nucleobases, by one, two or three nucleobases, wherein advantageously the 5′-terminal nucleobase(s) is/are absent.

### Claim at position 6

10-12. (canceled)

### Claim 13 (depends on 1)

The construct according to claim 1, wherein said second and third nucleic acid sequences have are selected from the group consisting of: SEQ ID NOs: 534 and 265; 534 and 358; 541 and 265; 541 and 358; and wherein said sequences of SEQ ID NOs: 265 and 358: may be shorter by one, two, three or four nucleobases, wherein optionally the 5′-terminal nucleobase(s) is/are absent.

### Claim at position 8

14-21. (canceled)

### Claim 22

The construct according to claim, wherein said first and second nucleic acid sequences each independently have a length of 18 to 21, 18 to 20, or 19 nucleotides.

### Claim at position 10

23-27. (canceled)

### Claim 28 (depends on 1)

The construct according to claim 1, which further comprises one or more ligands.

### Claim at position 12

29-36. (canceled)

### Claim 37 (depends on 1)

The construct according to claim 1, which comprises one, two, or three N-Acetyl-Galactosamine moieties.

### Claim at position 14

38-39. (canceled)

### Claim 40 (depends on 37)

The construct according to claim 37, wherein said ligand has the following structure:

### Claim 41

(canceled)

### Claim 42 (depends on 1)

The construct according to claim 1, which comprises 1 to 15 phosphorothioate or phosphorodithioate internucleotide linkages.

### Claim at position 18

43-46. (canceled)

### Claim 47 (depends on 1)

The construct according to claim 1, wherein at least one nucleotide is 2′ modified.

### Claim at position 20

48-61. (canceled)

### Claim 62 (depends on 47)

The construct according to claim 47, wherein said 2′ modified sugar is a 2-O-methyl modified sugar of a 2′-F modified sugar.

### Claim at position 22

63-69. (canceled)

### Claim 70 (depends on 5)

The construct according to claim 5, wherein all remaining nucleotides other than the labile sites contain either 2′-O-methyl modifications or 2′-F modifications in ribose moieties.

### Claim at position 24

71-72. (canceled)

### Claim 73 (depends on 1)

The construct of claim 1, wherein
(a) said first nucleic acid portion has a sequence selected from the first 19 nucleotides of an oligonucleotide selected from the group consisting of SEQ ID Nos. 1505-1758, or is represented by a nucleic acid sequence: 5′[phos] mU #fU #mG fA mA fU mG fA mA fA mC fG mA fC mU #fU #mC #fU #rC (SEQ ID No. 2075); or
5′[phos] mU #fU #mG fC mC fA mC fA mG fA mC fU mC fA mG fA #mG #mA #rG (SEQ ID No. 2076);
(b) said second nucleic acid portion is selected from the group consisting of SEQ ID Nos. 1759-1858, or is represented by a nucleic acid sequence 5′[phos] mG #fA #mU fA mG fU mU fG mU fA mA fA mC fA mG #fU #fU #fC #rC (SEQ ID No. 2077); or
5′[phos] mU #fU #mA fC mA fA mC fA mG fA mA fU mA fU mG #fG #mU #fA #rU (SEQ ID No. 2078);
(c) said fourth nucleic acid portion is selected from the group consisting of SEQ ID Nos.1859-1958, or is represented by a nucleic acid sequence: fC #mU #fG mU fU mU fA mC fA mA fC mU mA #mU #mC #[3XGalNAc](SEQ ID No. 2079); or
fC #mA #fU mA fU mU fC mU fG mU fU mG mU #mA #mA #[3XGalNAC](SEQ ID No. 2090); and/or
(d) said third nucleic acid portion is selected from the group consisting of (i) the last 15 nucleotides of each of SEQ ID Nos. 1505-1756, (ii) a last 14 nucleotides of SEQ ID No. 1757, and (iii) a last 11 nucleotides of SEQ ID No. 1758, or is represented by a nucleic acid sequence: fC mU fG mA fG mU fC mU fG mU fG mG mC #mA #mA #[3XGalNAc](SEQ ID No. 2080); or
fC mU fG mA fG mU fC mU fG mU fG mG mC #mA #mA #(SEQ ID No. 2081).

### Claim 74 (depends on 1)

The construct of claim 1 wherein said construct comprises a first strand selected from the group consisting of SEQ ID Nos. 2059-2066, and a second strand selected from the group consisting of SEQ ID Nos. 2067-2074.

### Claim 75 (depends on 74)

The construct of claim 74, wherein the first strand has a sequence:
(SEQ ID No. 2082)
5′[phos] mU# fU# mG fA mA fU mG fA mA fA mC
fG mA fC mU# fU# mC# fU# rC fC# mU# fG mU
fU mU fA mC fA mA fC mU mA# mU# mC#
[3XGalNAC];
(SEQ ID No. 2083)
5′[phos] mU# fU# mG fA mA fU mG fA mA fA mC
fG mA fC mU# fU# mC# fU# rC fC# mA# fU mA
fU mU fC mU fG mU fU mG mU# mA# mA#
[3XGalNAc];
(SEQ ID No. 2084)
5′[phos] mU# fU# mG fC mC fA mC fA mG fA mC
fU mC fA mG fA# mG# mA# rG fC# mU# fG mU
fU mU fA mC fA mA fC mU mA# mU# mC#
[3XGalNAc];
or
(SEQ ID No. 2085)
5′[phos] mU# fU# mG fC mC fA mC fA mG fA mC
fU mC fA mG fA# mG# mA# rG fC# mA# fU mA
fU mU fC mU fG mU fU mG mU# mA# mA#
[3XGalNAc];
and/or wherein the second strand has a sequence:
(SEQ ID No. 2086)
5′[phos] mG# fA# mU fA mG fU mU fG mU fA mA
fA mC fA mG# fU# fU# fC# rC fA# mG# fU mC
fG mU fU mU fC mA fU mU mC# mA# mA#
[3XGalNAc];
(SEQ ID No. 2087)
5′[phos] mU# fU# mA fC mA fA mC fA mG fA mA
fU mA fU mG# fG# mU# fA# rU fA# mG# fU mC
fG mU fU mU fC mA fU mU mC# mA# mA#
[3XGalNAc];
(SEQ ID No. 2088)
5′[phos] mG# fA# mU fA mG fU mU fG mU fA mA
fA mC fA mG# fU# fU# fC# rC fC mU fG mA
fG mU fC mU fG mU fG mG mC# mA# mA#
[3XGalNAc];
or
(SEQ ID No. 2089)
5′[phos] mU# fU# mA fC mA fA mC fA mG fA mA
fU mA fU mG# fG# mU# fA# rU fC mU fG mA
fG mU fC mU fG mU fG mG mC# mA# mA#
[3XGalNAc],
wherein Phos being phosphate; [mN], N being any nucleoside, designates 2′-OMe; [fN], N being any nucleoside, designates: 2′-F; [rA], N being any nucleoside, designates: 2′-OH; [#] designates a phosphorothioate connecting two adjacent nucleosides; and [3XGalNAc] designates a following ligand, as shown in square brackets:
and wherein 5Phos is optional.

### Claim 76 (depends on 1)

The construct according to claim 1, selected from the group consisting of SEQ ID Nos. 2059-2074.

### Claim 77 (depends on 1)

The construct according to claim 1, wherein the 3′ terminal positions of said first and said third nucleic acid sequences are replaced with an unmodified nucleotide.

### Claim at position 30

78-83. (canceled)

### Claim 84 (depends on 1)

The construct according to claim 1, wherein the total length of the construct is 30 to 35 nucleosides, optionally 33 or 34 nucleosides.

### Claim 85

(canceled)

### Claim 86 (depends on 1)

A pharmaceutical composition comprising a nucleic acid construct according to claim 1 and a pharmaceutically acceptable excipient, diluent, antioxidant, and/or preservative.

### Claim at position 34

87-88. (canceled)

### Claim 89 (depends on 86)

The pharmaceutical composition of claim 86, wherein said pharmaceutical composition furthermore comprises one or more further pharmaceutically active agents selected from the group consisting of: an agent which modulates the innate and/or the adaptive immune system; an oligomeric compound directed to an immune system target; compounds targeting the proximal complement or Lectin pathway; MASP-2 targeting compounds; C3-targeting compounds; Sutimlimab; Narsoplimab; Pegcetacoplan AMY-102; IONIS-FB-LRx-LPN023; Lapalizumab; Mini-FH/AMY-201 MicroCept; GLG561; and combinations thereof.

### Claim at position 36

90-95. (canceled)

### Claim at position 37

94-99. (canceled)

### Claim 96 (depends on 1)

A method of treating a disease or disorder comprising administration of a nucleic acid construct according to claim 1 to an individual in need of treatment of a disease or disorder requiring reduction of CFB and/or C5 expression.
